Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Firebrick Pharma Limited ( (AU:FRE) ) has provided an update.
Firebrick Pharma Limited has issued 2,745,240 ordinary fully paid shares at $0.063 per share, raising approximately $173,000, despite some funding commitments not being secured by the lead manager, Report Card Pty Ltd. This issuance, part of a placement announced in June 2025, reflects the company’s ongoing efforts to secure capital for its operations and market expansion, with no excluded information affecting investor assessments.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company has developed Nasodine Nasal Spray and is expanding its market reach in the United States, Singapore, Fiji, and the Philippines.
Average Trading Volume: 66,282
Technical Sentiment Signal: Sell
For a thorough assessment of FRE stock, go to TipRanks’ Stock Analysis page.